Ibogaine is a plant drug studied mainly for addiction [1]. In studies of people treated with medical care, opioid withdrawal fell sharply within about three days [2][3][4]. One of those studies also found less cocaine craving [2]. In veterans with brain injuries, PTSD scores fell by a wide margin [1]. The drug carries a serious risk to the heart's rhythm [5].

What is ibogaine?

Ibogaine comes from the root of Tabernanthe iboga, a shrub that grows in Central Africa [5]. It is the main alkaloid, a type of plant compound, in the root bark [5]. In Gabon and nearby countries, members of the Bwiti religion take large doses of the root as part of a coming-of-age rite [2].

Scientists in France first isolated ibogaine from the root as crystals in 1901 [6]. It has been sold as a medicine before. In the 20th century, a root extract with a small amount of ibogaine was sold in France as a stimulant, under the name Lambarene [2].

The addiction story began in the 1960s. People dependent on heroin tried ibogaine on their own. They found that it stopped the signs of opioid withdrawal [2]. Since then, most ibogaine research has looked at drug and alcohol problems [1]. Newer work has added veterans with brain injuries and PTSD [1].

People looking into ibogaine usually want to know how much of what they have heard holds up. This guide sets out what studies have found in people, one condition at a time, and how strong each finding is. The full study list has every major trial in one place. The history of ibogaine science covers the longer timeline.

How does ibogaine work in the brain?

Ibogaine attaches to many brain targets at once [7]. They include opioid receptors, NMDA receptors and nicotinic receptors [7]. It also binds to two kinds of serotonin receptor, and to the pumps that recycle serotonin and dopamine [7].

Most drugs tune in to one radio station. Ibogaine picks up several at once, each at low volume. Its grip on each target is moderate to weak [1]. The body breaks it down into noribogaine, which binds a similar set of targets [1].

Researchers are still mapping how these contacts lead to less drug-seeking [7]. In rodent studies, the receptor contacts alone do not seem to explain why the effects last so long [7]. The same team looked next at slower changes in brain growth factors, covered further down [7].

Research also tracks how the body handles ibogaine, and how its effects play out over hours and days [2][8]. The pharmacology guide goes into those details. The main ideas about withdrawal are compared in how ibogaine interrupts withdrawal.

What has ibogaine done for people in studies?

In human studies, the clearest result is fast relief from opioid withdrawal. Teams in St Kitts, Mexico and New Zealand each saw withdrawal ease within about three days of treatment [2][3][4]. Smaller sets of studies cover cocaine, alcohol and other drugs, and PTSD in veterans with brain injuries [1][2][9][10].

Opioid dependence

The opioid studies below largely predate the fentanyl era [11]. In St Kitts, doctors scored the outward signs of opioid withdrawal much lower 36 hours after one dose [2]. Opioid craving also fell on all five parts of a standard craving test by the end of the stay [2].

In Mexico, people rated their own withdrawal at 31 points before treatment and 14 about three days after [3]. At one month, half the group said they had used no opioids in the past 30 days [3]. Drug-use scores stayed better than at the start at every check for a year [3].

In New Zealand, self-rated withdrawal fell from about 25 points to about 14 within a day [4]. A year later, drug-use scores were far below where they started [4].

Over the longer term, some people stopped opioids entirely and many cut down [4][12]. In New Zealand, 45 percent reported some opioid use in the month before the twelve-month interview [4]. In a survey of people treated for heroin or prescription opioid use in Mexico, three in ten said they never used opioids again [12]. About half went back to opioids but used less than before [12].

One person enrolled in the New Zealand study died during treatment [4]. The coroner found the death very likely linked to ibogaine. The most likely cause was a heart rhythm problem [4].

Cocaine, alcohol and other drugs

In St Kitts, people dependent on cocaine said their craving for it dropped sharply by the end of the stay [2]. In those reached a month later, craving was still lower than before treatment [2].

A Brazilian team looked back at past patients who had used alcohol, cannabis, cocaine or crack [9]. They had taken ibogaine along with talk therapy [9]. When the team gathered the data, 61 percent had stopped using [9]. People treated more than once reported longer drug-free stretches than people treated once [9].

In a 2026 pilot study in people with alcohol use disorder, most said they drank less after ibogaine [10].

PTSD and brain injury in veterans

A Stanford-led team studied US special forces veterans with mostly mild brain injuries [1]. The veterans took ibogaine with magnesium [1]. One month later, average disability scores had dropped from about 30 to about 5. On that scale, 5 counts as no disability [1]. PTSD scores fell from about 32 to about 5 on a scale rated by clinicians [1]. Depression and anxiety scores fell by similarly large margins [1]. A close read of the Stanford study covers it in depth.

How strong is each finding?

Relief from opioid withdrawal has the most support. Three teams in three countries found the same pattern [2][3][4]. The scorecard below gives the strength of each finding. In St Kitts and the veterans study, the dose was one part of a larger process. Medical checks came before it, and trained staff watched over people during it [1][2].

ClaimEvidence typeSpeciesStrength
Opioid withdrawal eases within about three days of treatmentThree observational studies, no control groups: withdrawal scored in a subset of 22 of the 102 opioid-dependent people in St Kitts, 30 in Mexico, 14 in New Zealand [2][3][4]HumanESTABLISHED
Opioid craving lower at discharge and at one monthOne inpatient series, one-month follow-up incomplete [2]HumanPLAUSIBLE
Opioid drug-use scores still lower at twelve monthsTwo observational studies; 8 people completed every New Zealand interview [3][4]HumanPLAUSIBLE
Cocaine craving lower at discharge and at one monthOne inpatient series, 89 cocaine-dependent people, follow-up incomplete [2]HumanPLAUSIBLE
Longer abstinence from alcohol, cannabis, cocaine or crack, with psychotherapyOne retrospective review, 75 people, no control group [9]HumanPLAUSIBLE
Less drinking in alcohol use disorderOne open-label pilot, 9 people, 5 completed [10]HumanPLAUSIBLE
Lower disability, PTSD, depression and anxiety scores one month after treatment, in veterans with brain injuriesOne open-label study, 30 veterans, magnesium co-dosed; effect sizes d = 2.54 (PTSD), 2.80 (depression), 2.13 (anxiety) [1]HumanPLAUSIBLE
Ibogaine binds many brain targetsLaboratory binding studies [7]In vitroESTABLISHED
GDNF rises in the reward area a day after a high doseOne rat study, 6 animals per group [7]RatPLAUSIBLE
Ibogaine and noribogaine lengthen the heart's QT intervalHospital study with continuous monitoring [5]; noribogaine trial [8]HumanESTABLISHED

What does ibogaine do to the brain in animal studies?

In rodent studies, ibogaine cuts how much morphine, heroin, cocaine and alcohol the animals choose to take [7]. It also eases the withdrawal signs set off by drugs that block opioid receptors [7]. These results match the direction of the human opioid findings [2][7].

One line of rat research looks at growth factors. These are proteins that act like fertilizer for nerve cells. They help cells grow and hold on to their links with each other.

In rats, a high dose of ibogaine raised a growth factor called GDNF in the brain's reward area a day later [7]. A lower dose left GDNF unchanged in every region tested [7]. One idea under study is that GDNF keeps itself going in a loop after the drug has cleared [7].

In the same rat study, the genetic message for a second growth factor, BDNF, rose steeply [7]. The finished BDNF protein did not rise by a significant amount [7].

In rat nerve cells grown in a dish, noribogaine helps the cells sprout new branches [7]. Branching of this kind is one way nerve cells form new links [7].

How long does ibogaine stay in the body?

Ibogaine itself leaves the blood within hours. Its half-life, the time the body takes to clear half a dose, is about 1.6 to 6 hours [2].

The body turns it into noribogaine, which stays far longer [2]. Given on its own to people on methadone, noribogaine had a half-life of 24 to 30 hours [8].

Picture a match lighting a slow-burning log. Ibogaine is the match. It flares and is gone within hours. Noribogaine is the log, still giving off heat for days [2][8]. The noribogaine guide follows that long tail in detail.

A liver enzyme called CYP2D6 does the conversion [2]. People do not all run it at the same speed. Between 5 and 10 percent of people of European descent lack the gene for it [4]. In these slow processors, combined drug levels are expected to run about twice as high [4].

Both compounds affect the heart. They lengthen the QT interval, the heart's electrical reset between beats [5][8].

In a Dutch hospital study of people with opioid use disorder, the QT interval grew by about 95 milliseconds at its peak after one dose [5]. Half the patients passed 500 milliseconds [5]. In close to half, the lengthening lasted beyond a full day [5].

In the same methadone patients, noribogaine given alone also lengthened the QT interval, and the effect grew with the dose [8]. A long QT interval after ibogaine has been linked to sudden deaths [7].

What is ibogaine treatment like?

Ibogaine treatment moves through stages over one to three days [1][13]. A dreamlike stage begins between about half an hour and three hours after the dose [2][13]. It lasts about four to eight hours [1][13]. Most people keep their eyes closed for it [1].

In this first stage, many people see a stream of images drawn from their own past [13]. Among people treated for opioid or cocaine dependence in St Kitts, about four in ten saw scenes from childhood [2]. More than half felt linked to a higher power [2]. About six in ten saw images or changes in how things looked [2].

A quieter stage follows. It lasts roughly 8 to 20 hours [1][13]. The images fade, and attention turns to what came up. The mood is mostly calm and thoughtful [13]. Over the next one to three days, any leftover effects wear off [1].

The body goes through its own changes. In a Dutch hospital study of opioid treatment, every patient had a spell of severe, short-lived unsteadiness and needed help to walk [5]. In the veterans study, everyone had mild unsteadiness or a tremor that cleared within a day [1].

In the veterans study, four in ten were treated for a headache [1]. Nausea and vomiting were common in St Kitts [2]. Sleep can be hard for up to three days, and sleep medicine helps [13].

Looking back, most people in St Kitts rated the experience well. Nine in ten said it helped with their drug problem [2]. A similar share said it gave them insight [2]. Half felt cleansed or reborn [2].

If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.

Find a provider

Where the research goes next

Four directions stand out. The first is controlled trials, where people are assigned at random to ibogaine or a comparison. A 2026 review of thirty years of human research brings together the open-label results that such trials would put to the test [14].

The veterans team and the alcohol pilot team both name controlled trials as the next step [1][10]. Such trials would show how much of the benefit comes from ibogaine itself.

The second is protecting the heart. The veterans study gave magnesium before and after the dose, and heart monitors there picked up no QT lengthening large enough to see on screen [1]. In the alcohol pilot, the QT interval changed in five of nine people, and the authors call for strict heart checks and constant monitoring [10]. A trial that compares ibogaine with and without magnesium could test whether magnesium protects the heart.

The third is separating the drug from the care around it. The veterans also received other treatments during their stay in Mexico [1]. The Brazilian patients had talk therapy alongside ibogaine [9]. Future studies can measure what each part adds.

The fourth is reach beyond opioids. Cocaine, alcohol and PTSD each have early human signals [1][2][9][10]. Each condition needs its own trials, because a result in one does not transfer to another. The open questions guide sets out what those trials must answer.

Frequently asked questions

What is ibogaine made from?

Ibogaine comes from the root bark of Tabernanthe iboga, a Central African shrub [5]. It is the main alkaloid in the root bark [5]. The Bwiti religion uses the root in a coming-of-age rite [2].

Is ibogaine a psychedelic?

Researchers class ibogaine as an atypical psychedelic [1]. Its effects feel like a waking dream, so some call it an oneirogen, a drug that brings on dream states [1]. It acts on many brain targets at once [7].

Does ibogaine work for alcohol addiction?

In a 2026 pilot study of alcohol use disorder, most people said they drank less after ibogaine [10]. In Brazil, people who used alcohol or other drugs took ibogaine with talk therapy, and many stayed off drugs for months [9]. Both groups were treated under medical care [9][10].

What does ibogaine do for PTSD?

In a Stanford-led study of special forces veterans with brain injuries, PTSD scores fell from about 32 to about 5 a month after treatment [1]. Scores for low mood and anxiety fell by similarly large margins [1]. The veterans took ibogaine with magnesium, with medical staff on hand the whole time [1].

Is ibogaine safe?

Ibogaine lengthens the heart's QT interval, which has been linked to sudden deaths [7]. In a hospital study of opioid treatment, half the patients passed a QT of 500 milliseconds after a single dose [5]. Treatment needs heart checks first and constant heart monitoring during treatment. These lower the risk without removing it [2][5].

Safety. Ibogaine prolongs the heart's QT interval and can trigger dangerous arrhythmias. Treatment requires an EKG and bloodwork before dosing, continuous cardiac monitoring during, and medically trained staff present. Ibogaine is not safe to take unsupervised.
Disclaimer: This entry is general information, not medical advice.

References

  1. Cherian KN, Keynan JN, Anker L, et al. 2024, Nat Med 30(2):373-381. doi:10.1038/s41591-023-02705-w. PMID 38182784. PMC10878970. ClinicalTrials.gov NCT04313712. europepmc.org/article/PMC/PMC10878970
  2. Mash DC, Duque L, Page B, Allen-Ferdinand K. 2018, Front Pharmacol 9:529. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00529/full
  3. Brown TK, Alper K. 2018, Am J Drug Alcohol Abuse 44(1):24-36. PMID 28541119. doi.org/10.1080/00952990.2017.1320802
  4. Noller GE, Frampton CM, Yazar-Klosinski B. 2018, Am J Drug Alcohol Abuse 44(1):37-46. doi.org/10.1080/00952990.2017.1310218
  5. Knuijver T, Schellekens A, Belgers M, et al. 2022, Addiction 117(1). doi:10.1111/add.15448. PMC9292417. europepmc.org/article/PMC/PMC9292417
  6. Haller A, Heckel E. 1901, Comptes rendus hebdomadaires des séances de l'Académie des sciences (Paris) 133:850-853. "Sur l'ibogine, principe actif d'une plante du genre Tabernaemontana, originaire du Congo.". samorini.it/doc1/alt_aut/ek/haller-heckel-sur-l-ibogine-principe-actif-d-une-plante-du-genre-tabernaemontana-originaire-du-congo.pdf
  7. Marton et al. 2019, Front Pharmacol 10:193. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00193/full
  8. Glue P et al. 2016, Clin Pharmacol Drug Dev 5(6):460-468. doi:10.1002/cpdd.254. PMID 27870477. doi.org/10.1002/cpdd.254
  9. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. 2014, J Psychopharmacol 28(11):993-1000. doi:10.1177/0269881114552713. PMID 25271214. europepmc.org/article/MED/25271214
  10. Rocha JM, Maekawa RM, Reis JAS, Guerra LTL, Rossi GN, Rodrigues LS, Villanova B, et al. 2026, Trends Psychiatry Psychother. doi:10.47626/2237-6089-2026-1437. PMID 42520175. europepmc.org/article/MED/42520175
  11. Shen MR, Owusu-Boaitey K, Murphy ZD, Rains AN, Wang PR, Zhou DW, Suzuki J. 2026, Front Psychiatry 17:1909149. doi:10.3389/fpsyt.2026.1909149. PMID 42755825. PMC13581858. frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1909149/full
  12. Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. 2017, J Psychedelic Stud 1(2):65-73. doi:10.1556/2054.01.2017.009. PMID 30272050. PMC6157925. europepmc.org/article/PMC/PMC6157925
  13. Alper KR, Lotsof HS, Frenken GMN, Luciano DJ, Bastiaans J. 1999, Am J Addict 8:234-242. bibliography.maps.org/resources/download/17631
  14. Kervadec E, Bezo A, Serreau R, Strika-Bruneau L, Fauvel B, Amirouche A, et al. 2026, J Clin Psychopharmacol. doi:10.1097/jcp.0000000000002197. PMID 42228481. europepmc.org/article/MED/42228481